Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Mayne Pharma Group's share price for the quarter that ended in Dec. 2023 was €3.74. Mayne Pharma Group's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 81.2 Mil. Therefore, Mayne Pharma Group's market cap for the quarter that ended in Dec. 2023 was €303.9 Mil.
Mayne Pharma Group's quarterly market cap
increased
from Dec. 2022 (€181.8 Mil) to Jun. 2023 (€223.6 Mil) and
increased
from Jun. 2023 (€223.6 Mil) to Dec. 2023 (€303.9 Mil).
Mayne Pharma Group's annual market cap
declined
from Jun. 2021 (€323.0 Mil) to Jun. 2022 (€247.1 Mil) and
declined
from Jun. 2022 (€247.1 Mil) to Jun. 2023 (€223.6 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Mayne Pharma Group's Enterprise Value for Today is €170.4 Mil.
Mayne Pharma Group Market Cap Historical Data
The historical data trend for Mayne Pharma Group's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Mayne Pharma Group's Market Cap
For the Drug Manufacturers - General subindustry, Mayne Pharma Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayne Pharma Group's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mayne Pharma Group's Market Cap distribution charts can be found below:
* The bar in red indicates where Mayne Pharma Group's Market Cap falls into.
Mayne Pharma Group Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Mayne Pharma Group's Market Cap for the fiscal year that ended in Jun. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayne Pharma Group (HAM:HG6) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Mayne Pharma Group Market Cap Related Terms
Thank you for viewing the detailed overview of Mayne Pharma Group's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Branded Products (BPD) and Portfolio Products Division (PPD). The Portfolio Products Division distributes dermatology products (branded and generic) in the US on a portfolio basis, The Branded Products Division distributes branded women's health products in the US. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HAM:HG6 has been successfully added to your 